Patent Application
20100184840
THIS INVENTION relates to inhibition of viral gene expression. More specifically, this invention relates to a method of using RNA sequences to inhibit Hepatitis B Virus replication. Expression constructs containing sequences derived from endogenous micro RNAs (miRs) are used in the method to generate silencing sequences that are specific to HBV sequences.
RNA interference (RNAi) is an evolutionary conserved biological response to double-stranded RNA that has been described in plants [1], invertebrates [2-4] and in mammalian cells [5]. RNAi functions by directing the suppression of genes expressing homologous sequences to either endogenous or introduced RNAi effectors [6] with no effect on genes with unrelated sequences [7, 8]. RNAi is thought to be an ancient response pathway that plays a role in regulating the expression of protein-coding genes [8] and mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids. Naturally occurring small RNAs that activate RNAi are part of a complex network of micro RNAs (miRs), which are processed by Drosha and Dicer before effecting silencing of gene expression. These miRs have their effect by regulating translation of specific cellular mRNAs [9]. Processing of ‘rogue’ double stranded viral and cellular RNA by Dicer may also lead to formation of short interfering RNAs (siRNAs) [10-12]. These siRNAs are typically 21-23 by with 2 nucleotide 3′ overhangs [13] and activate RNAi to effect silencing of the potentially harmful RNA. miR sequences are initially transcribed as primary miRs (pri-miRs) from cellular DNA sequences using Pol II transcription regulatory sequences and RNA Polymerase II. Processing of pri-miRs by Drosha results in the formation of precursor miRs (pre-miRs) which in turn are cleaved by intracellular Dicer before the mature miRs (approximately 22 nt in length) induce silencing of gene expression. Drosha and Dicer are both RNase III enzymes that are essential for normal functioning of the RNAi pathway [14]. The post-transcriptional silencing action of RNAi has been reported to be more efficient than either ribozyme or antisense RNA action [15]. To cause gene silencing, miRs or one strand of an siRNA is incorporated into an RNA induced silencing complex (RISC). RISC includes Ago2 (an RNA endonuclease) and a helicase [16] amongst other subunits [17, 18]. Using the miR or antisense strand of siRNA as a hybridising guide sequence, RISC identifies the target mRNA [10, 19]. Generally, if the guide sequence is perfectly complementary to its cognate, then cleavage of the target occurs. If however there are mismatches in the hybrid within RISC, then translational suppression occurs. Gene silencing by siRNA-mediated methylation of promoter DNA sequences has also been shown to reduce gene transcription in mammalian cells [20].
Effecting RNAi in mammalian cells has, until recently, been a difficult undertaking. Double-stranded RNAs which are longer than 30 base-pairs trigger the non-specific interferon response pathway, which is mediated by the activation of dsRNA-dependent protein kinase (PKR) [21] and 2′,5′-oligoadenylate synthetase (2′5′OAS) [22]. This response pathway results in global repression of translation and leads ultimately to apoptosis [23]. To induce specific and significant gene silencing, intracellular delivery or production of siRNA or short hairpin RNA (shRNA) fragments of exact size is important. By introducing siRNAs as short synthetic annealed oligonucleotides (<30 bp) directly into mammalian cells, Tuschl and colleagues were successfully able to bypass the interferon pathway and effect RNAi in mammalian cell cultures [15].
Many of the studies undertaken to achieve gene silencing have used presynthesized RNAs. Typically, complementary RNA oligonucleotides are annealed in vitro to generate an exogenous source of siRNA for delivery into cells. Since synthetic oligoribonucleotides are not replenished naturally within a cell, to maintain an adequate intracellular concentration for sustained activity, these molecules need to be administered regularly. Synthetic oligoribonucleotides may be chemically altered to preserve their longevity in physiological fluids. However, these modifications may have adverse toxic effects in vivo [24]. Results from a number of studies suggest that siRNAs can be expressed endogenously as independent sense and antisense RNA strands [25, 26], as shRNAs [27-31] or as derivatives of naturally-occurring miRs [32, 33]. Transcription of miR genes naturally produces pri-miR sequences, which are processed in the nucleus by the enzyme Drosha to form pre-miR. Pre-miR is then transported to the cytoplasm via the exportin 5 pathway, where it is processed by Dicer to form mature miR. Since little is known about the promoters involved in miR expression, most studies have used the U6 small nuclear RNA [34] promoter [27] or more compact H1 promoter [8] or tRNAVal promoter [35]. These promoters are recognised by RNA Polymerase III, and are capable of constitutively producing effecters of RNAi. Pol III promoters have the advantage of containing all of their control elements upstream of the transcription initiation site, and this enables the generation of expression cassettes that produce transcripts of defined length. However, the constitutively active nature of Pol III promoter transcription may lead to saturation of the normal cellular RNAi pathway and resultant toxicity [36]. Pol II promoters can induce tissue- or cell-type-specific RNA expression but have the disadvantage of requiring control elements downstream of the transcription initiation site. Thus in addition to potentially therapeutic RNA, additional sequences derived from regulatory elements are included in the transcript. Previous studies have shown that these additional sequences inhibit the function of traditional shRNA molecules [37]. In fact, the silencing effect of transcribed shRNAs, or individual sense and antisense siRNA strands, is compromised by the presence of as few as 9 extra bases at the 5′ end, between the transcription start site and the 21 base pair hairpin [37]. There is at present no means of conveniently generating functional RNAi effectors from Pol II transcripts. Chemical RNA synthesis, in vitro transcription and use of Pol III-based cassettes are currently the preferred methods of generating short RNA sequences of precise length.
Terms used herein have their art-recognised meaning unless otherwise indicated. According to their use here, the following terms have meanings defined below.
Transcription
The process of producing RNA from a DNA template.
Nucleic Acid
The term “nucleic acid” refers to deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses analogues of natural nucleotides that hybridise to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.
Expression Cassette
A “recombinant expression cassette” or simply “expression cassette” is a nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements which permit transcription of a particular nucleic acid in the cell. The recombinant expression cassette can be part of a plasmid, virus or nucleic acid fragment. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed, and an operably linked promoter. In some embodiments, the expression cassette may also include an origin of replication and/or chromosome integration elements (e.g. a retroviral LTR).
Operably Linked
The term “operably linked” refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, enhancer or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
Promoter
A promoter is an array of DNA control sequences which is involved in binding of an RNA polymerase to initiate transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs away from the start site of transcription.
Pol II Promoter
A Pol II promoter is a DNA sequence that includes elements that are recognised by RNA Polymerase II to enable initiation of transcription by this enzyme. A Pol II promoter typically includes characteristic elements such as a TATA box.
Pol III Promoter
A Pol III promoter is a DNA sequence that includes elements that are recognised by RNA Polymerase III to enable initiation of transcription by this enzyme.
Transcription Termination Signal
A transcription termination signal is a DNA sequence that terminates transcription. These elements are different for RNA Polymerase II and RNA Polymerase III enzymes.
RNA Interference
The process by which the expression of a double stranded nucleic acid (including miR, siRNA, shRNA) causes sequence-specific degradation of complementary RNA, sequence-specific translational suppression or transcriptional gene silencing.
Target Recognition Sequence
As used herein, the term ‘target recognition sequence’ refers to a sequence derived from a gene, in respect of which gene the invention is designed to inhibit, block or prevent gene expression, enzymatic activity or interaction with other cellular or viral factors.
Guide Sequence
A short single stranded RNA fragment derived from an RNAi effecter, for example miR, siRNA, shRNA that is incorporated into RISC, and which is responsible for sequence-specific degradation or translation suppression of target RNA at a target recognition sequence.
RNAi Effecter
Any RNA sequence (e.g, shRNA, miR and siRNA) including its precursors, which can cause RNAi.
RNAi Effecter Processing Unit
RNA that includes sequences of an RNA effecter together with processing units (e.g. hammerhead ribozyme).
RNAi Effecter Processing Cassette
An RNAi effecter processing unit with operably linked promoter.
RNAi Precursor
Any RNA species that is processed to form a guide sequence, which may then be incorporated into RISC and effect RNAi.
Dicer
An RNAse III enzyme, which digests double stranded RNA and is responsible for maturation of RNAi precursors. For example, Dicer is responsible for acting on pre-miRs to form mature miR.
Drosha
Drosha is an RNase III enzyme that forms part of the nuclear microprocessor complex that recognises specific pri-miR secondary structures to cleave and release pre-miR sequences of approximately 60-80 nt.
RNAi-Encoding Sequence
A nucleic acid sequence which, when expressed, causes RNA interference.
Pri-miR
Pri-miR is a primary miR transcript that is typically derived from Pol II transcription. These sequences may originate from an independent miR transcription unit, a transcript that includes more than one miR precursor or an intronic miR precursor. These sequences are usually processed by Drosha within the cell nucleus to generate pre-miR.
Pre-miR
Pre-miR is the product of pri-miR processing by Drosha. Generally pre-miRs are 60-80 nt in length. Pre-miRs are exported from the cell nucleus by exportin-5. In the cytoplasm, pre-miRs are processed by Dicer to form mature miR.
miR
miRs are small RNA molecules of approximately 22 nt in length that are derived from processing of pri-miR and then pre-miR sequences.
mIR Expression Cassette
A miR expression cassette refers to a DNA sequence which encodes RNA that simulates endogenous miR. A pri-miR transcript is generated from the cassette and is processed by cellular mechanisms to generate pre-miR and mature miR.
Pri-miR Expression Cassette
A nucleic acid construct that encodes a pri-miR sequence.
shRNA
Short hairpin RNA (shRNA) is a short sequence of single stranded RNA which folds back on itself such that nucleotides from the two separate segments have base paired, and the resulting structure appears as the name describes. shRNA is a substrate for Dicer and effects RNAi (the double stranded region of the hairpin may include base mismatches i.e. non AU or GC pairs).
siRNA
Small interfering RNA (siRNA) consists of a short double-stranded RNA molecule. Typically a siRNA molecule comprises a 19 by duplex region with 3′ overhangs of 2 nt. One strand is incorporated into a cytoplasmic RNA-induced silencing complex (RISC). This directs the sequence specific RNA cleavage that is effected by RISC. Mismatches between the siRNA guide and its target may cause translational suppression instead of RNA cleavage. siRNA may be synthetic or derived from processing of a precursor by Dicer.
shRNA Precursor
A shRNA precursor is a hairpin RNA sequence that is processed intracellularly by Dicer to generate a shRNA molecule.
Multimeric Cassette
A tandem arrangement of monomeric units, which may include miR-encoding sequences.
In Silico
In silico refers to the laboratory conditions under which a reaction is carried out in a test tube (or equivalent vessel) and when no living cells are present.
Monomeric Unit
A nucleic acid sequence that encodes components of one RNAi effecter sequence.
Subsequence
The term “subsequence” in the context of a particular nucleic acid sequence refers to a region of the nucleic acid equal to or smaller than the specified nucleic acid, or a part thereof.
In Vitro Transcription
The transcription of a DNA molecule into RNA molecules using a laboratory medium which contains an RNA polymerase and RNA precursors.
Intracellular Transcription
The transcription of a DNA molecule into RNA molecules, within a living cell.
In Vivo Transcription
The transcription of a DNA molecule into RNA molecules, within a living organism.
Hybridisation
Nucleic acids are claimed that specifically hybridize to the nucleic acids herein disclosed under sufficient stringency conditions. Specific or selective hybridization is that hybridization wherein the nucleic acid binds the target nucleic acid with minimal background, nonspecific hybridization to non-target nucleic acids. Typically, the stringency of hybridization to achieve selective hybridization is about 5° C. to 20° C. below the Tm (the melting temperature at which half of the molecules dissociate from its partner), but it is further defined by the salt concentration and the permitivity of the solution. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The washing temperatures can similarly be used to achieve selective stringency, as is known in the art (Sambrook et al., 1987).
This invention describes a universally applicable method, which incorporates features of naturally occurring miRs into expression cassettes, to allow generation of an RNAi effecter from a Pol II or Pol III promoter.
According to one aspect of the invention there is provided a pri-miR expression cassette which includes a pri-miR sequence which includes an RNAi effecter sequence of predetermined length that regulates target gene expression which is included in a pri-miR sequence.
The pri-miR expression cassette may be expressed within a cell from Pol II or Pol III promoters.
In other words, broadly there is provided a pri-miR expression cassette, which includes:
a monomeric unit selected to generate a RNAi effecter sequence, and
said expression cassette being able to be expressed from Pol II or Pol III promoters.
The RNAi effecter sequence may be a miR-encoding sequence or a shRNA-encoding sequence.
The pri-miR expression cassette may be a multimeric RNA expression cassette.
The RNA expression cassette may be expressed using operably linked Pol II or Pol III promoters.
The monomeric unit may include miR-30, miR-31- or miR-122-derived sequences.
In a preferred embodiment, the RNA expression cassette may include said miR-30, miR-31- or miR-122-derived sequences that encode an RNAi effecter to a chosen target.
The RNA expression cassette may include any number of monomeric units.
The RNA expression cassette may include:
at least one further pri-miR-derived sequence, in addition to the first pri-miR-derived sequence; and
at least one further sequence encoding a RNAi effecter, in the context of a different pri-miR sequence.
The pri-miR expression cassette may include separate sets of sequences encoding RNAi effecter molecules that cause sequence-specific translation inhibition.
The pri-miR expression cassette may include separate sets of sequences encoding RNAi effecter molecules that cause sequence-specific transcriptional silencing.
The siRNA sequences or RNAi precursor molecules that effect sequence-specific translation inhibition, may include target recognition sequences derived from Hepatitis B Virus (HBV) X gene (HBx) or Hepatitis C Virus (HCV). The target recognition sequences may be derived from at least two specific sites of the HBV HBx gene.
According to another aspect of the invention there is provided an isolated nucleic acid sequence encoding the pri-miR expression cassette of the invention. The nucleic acid sequence may include at least one of the sequences selected from the group consisting of SEQ ID NOs: 3, 4, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 38, 39 and 106, the complementary sequences thereof (SEQ ID NOs: 109-131 and 169-171) or the RNA sequences thereof (SEQ ID NOs: 135-163, 167, 168 and 172).
The nucleic acid sequence may include SEQ ID NO. 3 or 135; a nucleic acid sequence complementary to SEQ ID NO. 3 or 135; a nucleic acid sequence which hybridizes specifically to SEQ ID NO. 3 or 135; a homologous sequence of a hepadnavirus; or a nucleic acid sequence which has at least 90% sequence identity to one of said sequences.
The nucleic acid sequence may include SEQ ID NO. 4 or 136; a nucleic acid sequence complementary to SEQ ID NO. 4 or 136; a nucleic acid sequence which hybridizes specifically to SEQ ID NO. 4 or 136; a homologous sequence of a hepadnavirus; or a nucleic acid sequence which has at least 90% sequence identity to one of said sequences.
Preferably, the nucleic acid sequence may have at least 95% sequence identity to said sequence.
According to a further aspect of the invention there is provided a nucleic acid sequence encoding a target sequence, wherein the nucleic acid sequence is 5′-CCGTGTGCACTTCGCTTCACCTCTG-3′ (SEQ ID NO: 38); a complementary nucleic acid sequence; a nucleic acid sequence which hybridizes specifically to said sequence; or a nucleic acid sequence which has at least 90% sequence identity to one of said sequences.
The nucleic acid sequence may have at least 95% sequence identity to said sequence.
According to a further aspect of the invention there is provided a nucleic acid sequence encoding a target sequence, wherein the nucleic acid sequence is 5′-TGCACTTCGCTTCACCTCTGCACGT-3′ (SEQ ID NO: 39); a complementary nucleic acid sequence; a nucleic acid sequence which hybridizes specifically to said sequence; or a nucleic acid sequence which has at least 90% sequence identity to one of said sequences.
The nucleic acid sequence may have at least 95% sequence identity to said sequence.
According to another aspect of the invention there is provided a method of inhibiting expression of at least one target RNA transcript having at least one target recognition sequence, the method including steps of:
providing a nucleic acid sequence encoding an expression construct having a pri-miR expression cassette according to the invention, wherein RNAi effecter domains of the miRs recognise specific sites within the target;
expressing the nucleic acid sequence encoding the pri-miR expression cassette to produce the mature miR;
allowing the processed RNAi effector molecule to contact at least one target RNA transcript, whereby the RNAi effecter molecule, directs the inhibition of expression of the target RNA transcript(s).
The step of expressing the nucleic acid sequence, the step of allowing the cleaved RNAi effecter molecule, or precursor thereof, to contact at least one target RNA transcript and the inhibition of expression of the target RNA transcript(s) may occur substantially simultaneously.
According to an embodiment of the invention there is provided a vector having incorporated therein a nucleic acid sequence encoding the pri-miR expression cassette of the invention.
The vector may be any suitable vector known to someone skilled in the art, e.g. a viral or non-viral vector.
According to another embodiment of the invention there is provided a composition which includes the vector of the invention and a physiologically acceptable carrier.
According to another aspect of the invention there is provided a cell which includes an RNA sequence encoding a RNAi effecter sequence or precursor according to the invention. The invention also extends to a cell including DNA encoding the RNA sequences from which, according to the invention, RNAi effecter molecules are derived.
According to a further aspect of the invention there is provided a cell which includes the vector described above.
According to another aspect of the invention there is provided a method of regulating the expression of DNA, the method including the steps of:
introducing into a cell a vector having incorporated therein a nucleic acid sequence encoding a pri-miR expression cassette of the invention, wherein a RNAi effecter sequence, or sub-sequence thereof, recognises at least one target RNA transcript containing at least one target recognition sequence or subsequence thereof; and
causing the vector to express the nucleic acid sequence encoding the pri-miR expression cassette, whereby, upon expression, the RNA cassette or subsequence thereof is cleaved into its RNAi effecter, and whereby the processed RNAi effecter recognises the target RNA transcript, thereby inhibiting the expression of the target sequence or subsequence thereof.
According to another aspect of the invention there is provided a method of inhibiting the in vivo expression of DNA, the method including the steps of:
introducing a vector within an organism, wherein the vector has incorporated therein a nucleic acid sequence encoding a pri-miR expression cassette in accordance the invention, wherein a RNAi effecter, or subsequence thereof, recognises at least one target RNA transcript containing at least one target recognition sequence or subsequence thereof comprising an RNA interference recognition site; and
causing the vector to express the nucleic acid sequence encoding the pri-miR expression cassette or subsequence thereof, whereby, upon expression, the RNA cassette or subsequence thereof is cleaved into its RNAi effecter precursor sequence, and whereby the RNAi effecter recognises the target RNA transcript, thereby inhibiting expression of the target sequence.
According to another aspect of the invention there is provided a method of inhibiting the in vivo expression of DNA, the method including the steps of:
introducing a vector within an organism, wherein the vector has incorporated therein a nucleic acid sequence encoding a pri-miR expression cassette in accordance the invention, wherein a RNAi effecter, or subsequence thereof, recognises at least one target DNA sequence containing at least one target recognition sequence or subsequence thereof comprising an inhibition recognition site; and
causing the vector to express the nucleic acid sequence encoding the pri-miR expression cassette or subsequence thereof, whereby, upon expression, the RNA cassette or subsequence thereof is cleaved into its RNAi effecter precursor sequence, and whereby the RNAi effecter inhibits transcription from the target sequence.
According to another aspect of the invention there is provided a method of inhibiting the in vitro expression of DNA, the method including the steps of:
introducing a vector within a cell, wherein the vector has incorporated therein a nucleic acid sequence encoding a pri-miR expression cassette or subsequence thereof according to the invention, wherein a RNAi effecter sequence, or subsequence thereof, recognises at least one target RNA transcript containing at least one target recognition sequence or subsequence thereof comprising an RNA interference recognition site; and
causing the vector to express the nucleic acid sequence encoding the pri-miR expression cassette or subsequence thereof, whereby, upon expression, the RNA cassette or subsequence thereof is cleaved into a RNAi effecter precursor sequence, and whereby the RNAi effecter, recognises the target RNA transcript, thereby inhibiting expression of the target sequence.
The multimeric pri-miR expression cassette may include any number of monomeric units.
The target recognition sequence may be derived from the HBx open reading frame of Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). More specifically, the target recognition sequence of the RNAi effecter sequence may be derived from at least two regions located within the HBx open reading frame of HBV.
According to a further aspect of the invention, there is provided the use of a pri-miR expression cassette as described herein in the manufacture of a preparation for treating Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection, or diseases caused thereby.
According to another aspect of the invention, there is provided a composition for use in a method of treating Hepatitis B virus (HBV) or Hepatitis C Virus (HCV) infection, or diseases caused thereby, said composition including a pri-miR expression cassette as described herein, and said method including administering a therapeutically effective amount of said composition.
According to a further aspect of the invention there is provided a method of treating Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection, or diseases caused thereby, said method including administering to a subject a therapeutically effective amount of a pri-miR expression cassette in accordance with the invention.
The invention will now be described, by way of non-limiting example, with reference to the accompanying drawings. In the drawings.
Homo sapiens PRI MIR 31
Homo sapiens PRI MIR 122
Homo sapiens MIR 30
Homo sapiens PRI MIR 31 RNA
Homo sapiens PRI MIR 122 RNA
Homo sapiens MIR 30 RNA
Activation of the RNAi pathway to effect specific gene silencing has prompted enthusiasm for the potential of nucleic acid-based HBV treatment. RNAi involves specific and powerful gene silencing through predictable complementary interaction between RNAi effecters and their targets. Naturally, RNAi plays an important role in regulation of gene expression through processing of endogenous miRs, which control several cellular processes that include organogenesis, apoptosis, cell proliferation and tumorigenesis. miRs are transcribed by Pol II as pri-miR hairpin-like structures, which are then processed to form precursor miRs (pre-miRs) within the nucleus. This step is catalyzed by Drosha (an RNAse III enzyme) together with Di George critical region 8 protein (DGCR8), which is its double stranded RNA binding (dsRBD) partner. Some endogenous miRs are polycistronic and more than one mature miR, with different may be generated from a single transcript. After export from the nucleus, pre-miRs are processed by Dicer with associated dsRBD TAR RNA-binding protein. The resulting 19-24 by duplex is handed on to the RNA induced silencing complex (RISC) before selection of one strand as the mature miR guide. miRs are usually not entirely complementary to their targets and bind to the 3′ untranslated regions of cognate mRNA to induce translational suppression. When base pairing between guide and target is perfectly matched, the Ago2 component of RISC exerts silencing through site-specific cleavage of the guide complement.
The specific and powerful gene silencing that may be induced by RNAi has prompted investigation of RNAi-based therapeutic modalities to inhibit expression of pathology-causing genes, which include those of viruses such as HBV and hepatitis C virus (HCV). Typically, exogenous RNAi-inducing sequences have been either synthetic short interfering RNA (siRNA) duplexes or expressed shRNA sequences. Synthetic siRNAs are similar to Dicer cleavage products and cause gene silencing by direct activation of RISC. shRNAs enter the RNAi pathway at an earlier stage and act as pre-miR mimics. Constitutively active Pol III promoters have been favored to transcribe shRNAs because of their ability to generate short, defined transcripts with a minimal requirement for regulatory elements within the transcript-encoding sequences. Several sites of the HBV genome have been targeted with synthetic and expressed RNA sequences and impressive knockdown of markers of viral replication has been shown. However, recent demonstration that U6 Pol III-expressed anti HBV shRNAs cause serious toxicity in vivo as a result of saturating the endogenous miR pathway is an important concern for therapeutic application of expressed RNAi sequences. Tissue-specific and inducible Pol II promoters may therefore be preferable to Pol III regulatory elements as they provide a better means of transcription control and dose regulation of expressed RNAi effecters. Some reports have demonstrated efficient silencing by Pol II RNAi expression cassettes, but this approach has been hampered by unpredictable and variable silencing efficacy of conventional hairpin sequences. Sequences upstream and downstream of the hairpins, which are incorporated into Pol II-derived transcripts, may interfere with processing of the silencers. To improve transcription control of potentially therapeutic sequences, we have taken advantage of the natural Pol II-mediated transcriptional control of cellular miRs. Anti HBV sequences were incorporated into expression cassettes that encode mimics of pri-miR-31 or pri-miR-122. Potent silencing of markers of viral replication was achieved in vitro and in vivo when anti HBV pri-miR shuttle expression cassettes were placed under control of Pol II liver specific promoters. Also, these shuttle sequences enable production of multimeric silencing sequences that target different sequences simulataneously.
The invention describes a method of inhibiting or silencing hepatitis virus (in particular hepatitis B or C virus) expression using expression cassettes that encode mimics of primary micro RNAs incorporating one or more target sequences of the hepatitis virus.
The anti-hepatitis primary micro RNA (pri-miR) expression cassette generally includes a DNA sequence encoding an artificial (i.e. engineered) pri-miR sequence which mimics a naturally occurring miR sequence (such as miR-30, miR-31 and mi-R-122), the guide sequence of the naturally occurring pri-miR sequence (and the complementary sequence of the guide sequence) having been replaced with a sequence which targets hepatitis virus.
The expression cassette includes a Pol II promoter, which may be a constitutive promoter, such as CMV, or a tissue specific promoter, such as the liver-specific tissue promoters alpha-1-antitrypsin (A1AT) promoter, Factor VIII (FVIII) promoter, HBV basic core promoter (BCP) and PreS2 promoter. The expression cassette may also include a promoter/transcription regulatory sequence and/or a termination signal.
The selection of target sites that were used against the hepatitis B virus (HBV) were based on the conservation of the sequences amongst all the HBV genotypes, and also on the predicted susceptibility of the targets to short hairpin RNAs (shRNAs) silencing. This was analysed using an algorithm that is available online through the City of Hope Hospital (Duarte, Calif.) (Neale et al [45]). Although the hepatitis B virus is relatively well-conserved, there are many different known genotypes, and hence sequences of 90% and 95% to the target sequences described in the examples are claimed so as to also cover the targets in these other genotypes.
The expression cassette may be incorporated into a viral or non-viral vector, which may be used to introduce the expression cassette into a host cell or organism.
The expression cassette is intended to be used to treat or prevent hepatitis infection, in particular in a human, and may be incorporated into a pharmaceutical composition, such as an anti hepatitis medicament which also includes a pharmaceutically acceptable adjuvant and/or carrier.
The present invention is further described by the following examples. Such examples, however, are not to be construed as limiting in any way either the spirit or scope of the invention. Hepatitis B targets 5, 6, 8, 9 and 10 were tested for silencing with miRs, but the other targets described herein have been subjected to less complicated shRNA silencing tests. A person skilled in the art will understand that if the shRNAs work then the miRs will also do so.
The pri-miR expression cassettes were designed by replacing the guide sequences of naturally occurring miR-31 (SEQ ID NOs: 1/107/133) and miR-122 (SEQ ID NOs: 2/108/134) with the guide sequence targeting an HBV sequence (SEQ ID NO: 11/109/141). The entire sequence of the encoded anti HBV pri miR sequences are given in SEQ ID NOs: 3 (135) and 4 (136). The wild-type sequences of the miR were maintained as far as possible and computer-aided prediction [38] of secondary structure of the transcripts did not differ significantly from that of their respective wild-type miRs. The final cassettes contained 51 nucleotides of wild-type sequences flanking either end the pre-miR (Zeng and Cullen, 2005). To facilitate cloning of the miR cassettes restriction sites for Nhe I and Spe I were included at their 5′ and 3′ ends, respectively. A schematic illustration of the targeted genomic site of HBV and also the pri-miR expression cassettes are indicated in
1. Generation of Cassettes Encoding miR Sequences that Target HBV miR-derived anti HBV sequences. DNA encoding pre-miR-31 and pre-miR-122 containing the guide sequence targeting Hepatitis B Virus (HBV coordinates 1781 to 1801) (SEQ ID NOs: 3 and 4) (
The primer extended products were subjected to agarose gel electrophoresis (1% gel), excised and extracted from the gel slice using Qiagen's MinElute™ Gel Extraction Kit (Qiagen, Germany). Approximately 100 ng of purified pre-miR-31/5 and pre-miR-122/5 was used as template and amplified with forward and reverse pri-miR-31 and pri-miR-122 primers.
Amplification of U6 Pol III promoter sequences. The U6 promoter was also amplified with the following primers: U6 F 5′-GAT CAG ATC TGG TCG GGC AGG AAG AGG GCC-3′ (SEQ ID NO: 48) and U6 R 5′-GCT AGC GGT GTT TCG TCC TTT CCA CA-3′ (SEQ ID NO: 49). Thermal cycling parameters were as before. Amplicons were subjected to agarose gel electrophoresis (1% gel), excised and purified from the gel slice using the MinElute™ Gel Extraction kit from Qiagen.
Propagation of miR and U6 sequences. The DNA fragments encoding pri-miR-31/5, pri-miR-122/5 (SEQ ID NOS: 3 and 4) and the U6 promoter (SEQ ID NO: 5) were ligated into pTZ-57R/T (InsTAclone™ PCR Cloning Kit, Fermentas, Hanover, Md., USA) to generate pTZ-57R/T pri-miR-31/5 and pTZ-57R/T pri-miR-122/5 respectively. pTZ-U6 was generated similarly by insertion of the amplified U6 Pol III promoter sequence into pTZ. Ligation and selection were carried out according to the manufacturer's instructions. Briefly, the ligation reactions were incubated at 22° C. for 2-3 hours. Chemically competent E. coli were transformed with the ligation mix, plated on ampicillin, IPTG, X-gal positive LB agar plates and the plates incubated at 37° C. overnight. Clones positive for insert and in the reverse orientation (relative to the β-galactosidase gene) were sequenced according to standard dideoxy chain termination protocols (Inqaba Biotechnology, South Africa).
Anti HBV miR expression cassettes. To generate Pol III-driven pri-miR vectors the sequences encoding pri-miR-31/5 and pri-miR-122/5 were cloned downstream of the U6 promoter. To generate U6 pri-miR-31/5, pri-miR-31/5 was excised from pTZ-57R/T pri-miR-31/5 by digesting with Nhe I and Sca I and inserted into pTZ-U6 which had been digested with Spe I and Sca I. U6 pri-miR-122/5 was generated by excising pri-miR-122/5 from pTZ-57R/T pri-miR-122/5 with Nhe I and EcoRI and inserting it into pTZ-U6 which had been digested with Spe I and Sca I. The generation of pHBx shRNA 5 has been previously described [39] and involved a two step PCR reaction in which the U6 Pol III promoter was amplified together with downstream hairpin-encoding sequence and then inserted into pTZ-57R/T (InsTAclone™ PCR Cloning Kit, Fermentas, WI, USA).
Pol II-driven pri-miR vectors were generated by cloning pri-miR-31/5 and pri-miR-122/5 sequences downstream of the CMV promoter of pCI-neo (Promega, WI, USA). CMV pri-miR-31/5 was generated by excising pri-miR-31/5 from pTZ-57R/T pri-miR-31/5 with Sal I and Nhe I and ligating it into pCI-neo which had been digested with Xho I and Xba I. CMV pri-miR-122/5 was generated by excising pri-miR-122/5 from pTZ-57R/T pri-miR-122/5 with Nhe I and Xba I digestion followed by ligation into pCI-neo which had been digested with the same restriction enzymes.
Expression cassettes targeting different sites within the HBx open reading frame (sites 8 and 9) were generated according to similar procedures. The HBV sequence (SEQ ID NO: 6, ACCESSION AY233296) co-ordinates targeted by each of these cassettes were as follows: pTZ-57R/T pri-miR-31/8 targeting HBV 1678-1698 (SEQ ID NO: 7 (137)), pTZ-57R/T pri-miR-31/9 targeting HBV 1774-1794 (SEQ ID NO: 8 (138), pTZ-57R/T pri-miR-122/6 targeting HBV 1678-1700 (SEQ ID NO: 9 (139)) and pTZ-57R/T pri-miR-122/10 targeting HBV 1774-1796 (SEQ ID NO: 10 (140)).
Transfection of cultured cells with plasmids encoding miR-31/5 and miR122/5. HEK293 cells were propagated in DMEM supplemented with 10% FCS, penicillin (50 IU/ml) and streptomycin (50 μg/ml) (Gibco BRL, UK). On the day prior to transfection, 1 500 000 HEK293 cells were seeded in dishes of 10 cm diameter. Transfection was carried out with 10 μg of shRNA- or miR-expressing plasmid using Lipofectamine (Invitrogen, CA, USA) according to the manufacturer's instructions.
Northern blot analysis. HEK293 cells were harvested 4 days after transfection and total RNA was extracted using Tri Reagent (Sigma, Mich., USA) according to the manufacturer's instructions. Twenty μg of RNA was resolved on urea denaturing 12.5% polyacrylamide gels and blotted onto nylon membranes. Radioactively labelled DNA oligonucleotides were run alongside the cellular RNA and used as size indicators. Blots were hybridised to a probe that was designed to be specific to the putative mature miR-31/5 and miR-122/5 products. The sequence of this probe oligonucleotide was: 5′ GACTCCCCGTCTGTGCCTTCTCA 3′ (SEQ ID NO: 50). To verify equal loading of the lanes with cellular RNA, the blots were stripped and reprobed with an oligonucleotide complementary to endogenous U6 snRNA. The sequence of the U6 snRNA probe was: 5′ TAGTATATGTGCTGCCGAAGCGAGCA 3′ (SEQ ID NO: 51). All probes were radioactively labelled according to standard procedures using polynucleotide kinase and γ-32P ATP.
Detection of processed sequences.
Target plasmids. pCH-9/3091 has been described previously [42]. It contains a greater than genome length HBV sequence, which is similar to the HBV A1 subgenotype consensus, and generates a 3.5 kb HBV pregenomic transcript from its CMV promoter. By replacing the preS2/S ORF of pCH-9/3091 with Firefly luciferase-encoding DNA, the pCH Firefly Luc vector was prepared similarly to the previously described procedure employed to generate pCH GFP [43]. Briefly, a Firefly luciferase sequence was amplified from psiCheck2 (Promega, WI, USA) using PCR. The primer combination to amplify the region encoding Firefly luciferase was:
The forward primer comprised sequences complementary to HBV sequences from co-ordinates 129-159 (including a naturally occurring XhoI restriction site) and 5′ Firefly luciferase sequences. In this primer, the position of the Firefly luciferase initiation codon is equivalent to that of the translation initiation codon of the middle HBs protein. The reverse primer included sequences complementary to the 3′ end of the Firefly luciferase ORF as well as a SpeI restriction site. The PCR primer sequences were as follows:
XhoI and SpeI sites incorporated by the primers are indicated in bold. The PCR product was cloned into pTZ-57R/T (InsTAclone™ PCR Cloning Kit, Fermentas, WI, USA). The Firefly luciferase sequence was then excised from pCI-EGFP with XhoI and SpeI and inserted into the XhoI and SpeI sites of pCH-9/3091 to generate pCH-Firefly Luc. The psiCheck-HBx target plasmid was prepared by directed insertion of the XhoI-Not I digested HBx fragment from pCI-neo HBx [44] into the plasmid psiCheck2 (Promega, WI, USA) such that the HBx ORF is within the 3′ untranslated region (UTR) of the Renilla Luciferase cassette.
Cell culture. Huh7 cells were maintained in RPMI medium supplemented with 2.5% fetal calf serum (FCS), penicillin (50 IU/ml) and streptomycin (50 μg/ml) (Gibco BRL, UK). HEK293 cells were propagated in DMEM supplemented with 10% FCS, penicillin (50 IU/ml) and streptomycin (50 μg/ml) (Gibco BRL, UK). On the day prior to transfection, 250 000 HEK293 cells or 150 000 Huh7 cells were seeded in wells of 2 cm diameter. Transfection was carried out using Lipofectamine (Invitrogen, CA, USA) according to the manufacturer's instructions. To determine effects of miR-31/5 and miR122/5-encoding plasmids, Huh7 cells were transfected with a combination of 6 μg of pCH-9/3091 [42] or pCH Firefly Luc target vector and 2 μg of miR-31/5 and miR122/5 pTZ-derived plasmid or plasmid lacking the miR cassettes. In the case of transfections with the pCH Firefly Luc target vector, a plasmid that constitutively produces Renilla luciferase under control of the CMV promoter was included to control for transfection efficiency (pCMV-Ren vector, which was a gift from Dr John Rossi, City of Hope Hospital, Duarte, Calif. USA). HBV surface antigen (HBsAg) secretion into the culture supernatants was measured using the Monolisa (ELISA) immunoassay kit (BioRad, CA, USA). A plasmid vector that constitutively produces EGFP [43] was also included in each cotransfection and equivalent transfection efficiencies were verified by fluorescence microscopy. The activities of Renilla and firefly luciferase were measured with the dual luciferase assay kit (Promega, WI, USA) and using the Veritas dual injection luminometer (Turner BioSystems, CA, USA).
miR-mediated inhibition of HBV s antigen (HBsAg) secretion from transfected cells. Initially, to assess efficacy against HBV in vitro, Huh7 cells were cotransfected with miR-31/5- and miR-122/5-expressing vectors together with the pCH-9/3091 HBV target plasmid [42]. The HBx sequence is common to all HBV transcripts (
miR-mediated inhibition of Firefly luciferase activity in transfected cells. The data derived from analysis of HBsAg secretion of transfected cells (
Hydrodynamic injection of mice. The murine hydrodynamic tail vein injection (HDI) method was employed to determine the effects of miR plasmid vectors on the expression of HBV genes in vivo. Experiments on animals were carried out in accordance with protocols approved by the University of the Witwatersrand Animal Ethics Screening Committee. A saline solution comprising 10% of the mouse's body mass was injected via the tail vein over 5-10 seconds. This saline solution included a combination of three plasmid vectors: 5 μg target DNA (pCH-9/3091); 5 μg pCI-neo plasmid DNA (Promega WI, USA) that lacks HBV sequences or 5 μg anti HBV sequence (p U6 shRNA 5, pCMV miR-31/5 or pCMV miR-122/5 plasmid); and 5 μg pCI neo EGFP (a control for hepatic DNA delivery, which constitutively expresses the enhanced Green Fluorescent Protein (eGFP) marker gene [43]). After aborting investigations on animals where injections were suboptimal, each experimental group comprised 5-8 mice. Blood was collected under anaesthesia by retroorbital puncture on days 3 and 5 after HDI. Serum HBsAg concentration was measured using the Monolisa (ELISA) immunoassay kit (BioRad, CA, USA) according to the manufacturer's instructions. To measure effects of miR shuttle sequences on circulating viral particle equivalents (VPEs), total DNA was isolated from 50 μl of the serum of mice on days 3 and 5 after HDI and viral DNA determined using quantitative PCR according to previously described methods [39]. Briefly, total DNA was isolated from 50 μl of mouse serum using the Total Nucleic Acid Isolation Kit and MagNApure instrument from Roche Diagnostics. Controls included water blanks and HBV negative serum. DNA extracted from the equivalent of 8 μl of mouse serum was amplified using SYBR green Taq readymix (Sigma, Mo., USA). Crossing point analysis was used to measure virion DNA concentrations and standard curves were generated using EuroHep calibrators [45]. The HBV surface primer set was: HBV surface forward: 5′-TGCACCTGTATTCC ATC-3′ (SEQ ID NO: 56) and HBV surface reverse: 5′-CTGAAAGCCAAACAGTGG-3′ (SEQ ID NO: 57). PCR was carried out using the Roche Lightcycler V. 2. Capillary reaction volume was 20 μl and thermal cycling parameters consisted of a hot start for 30 sec at 95° C. followed by 50 cycles of 57° C. for 10 sec, 72° C. for 7 sec and then 95° C. for 5 sec. Specificity of the PCR products was verified by melting curve analysis and agarose gel electrophoresis.
The livers were harvested after sacrificing mice at 5 days after HDI. Total DNA was extracted from the liver according to standard procedures [46]. DNA was subjected to standard agarose gel electrophoresis without restriction digestion before processing for Southern blot analysis using Rapid-hyb buffer (Amersham, UK). To generate a probe, HBV X open reading frame DNA was amplified with the following probes: HBx Forward: 5′-GATCAAGCTTTCGCCAACTTACAAGGCCTTT-3′ (SEQ ID NO: 58) and HBx Reverse: 5′-GATCTCTAGAACAGTAGCTCCAAATTCTTTA-3′ (SEQ ID NO: 59). PCR products were purified and used as template for random-primed labelling with the HexaLabel™ DNA Labelling kit (Fermentas, Md., USA) according to the manufacturer's instructions. Fixed frozen liver sections were processed for detection of eGFP according to standard procedures.
The HBV DNA replication intermediates were measured in representative liver tissue of 2 animals from each group that had been subjected to HDI experimentation. The results of this analysis are shown in
Cell culture, transfection and RNA extraction. HEK293 cells were cultured and transfected as described above. Briefly, cells were maintained in DMEM supplemented with 10% FCS, penicillin (50 IU/ml) and streptomycin (50 μg/ml) (Gibco BRL, UK). On the day prior to transfection, 250 000 HEK293 cells were seeded in dishes of 2 cm diameter. Transfection was carried out with 800 ng of shRNA- or miR-expressing plasmid using Lipofectamine (Invitrogen, CA, USA) according to the manufacturer's instructions. As a positive control for the induction of the IFN response, cells were also transfected with 800 ng poly (I:C) (Sigma, Mich., USA). Two days after transfection, RNA was extracted with Tri Reagent (Sigma, Mich., USA) according to the manufacturer's instructions.
Real time quantitative PCR of interferon response genes. To amplify oligoadenylate synthase-1 (OAS-1), interferon-β (IFN-β), p56 and glyceraldehydes-3 phosphate dehydrogenase (GAPDH) cDNA, the procedures described by Song et al [47] were used. All qPCRs were carried out using the Roche Lightcycler V. 2. Controls included water blanks and RNA extracts that were not subjected to reverse transcription. Taq readymix with SYBR green (Sigma, Mo., USA) was used to amplify and detect DNA during the reaction. Thermal cycling parameters consisted of a hotstart for 30 sec at 95° C. followed by 50 cycles of 58° C. for 10 sec, 72° C. for 7 sec and then 95° C. for 5 sec. Specificity of the PCR products was verified by melting curve analysis and agarose gel electrophoresis. The primer combinations used to amplify IFN response-related mRNA of human HEK293 cells were as follows:
Cell culture, transfection and RNA extraction. HEK293 and Huh7 cells were cultured and transfected as described above. On the day prior to transfection, 250 000 HEK293 cells were seeded in dishes of 2 cm diameter. To assess effects of miR-31/5- and miR-122/5-expressing plasmids on independent RNAi-mediated silencing, cells were seeded into 24-well dishes at a density of 35-40% then transfected with 80 ng of psi-CHECK-8T, 40 ng of pCMV miR-31/8 and 780 ng of shRNA 5 or miR 5 expression plasmids. Plasmid dose effects of pU6 shRNA 5 on independent silencing by pCMV miR-31/8 was determined by transfecting pU6 shRNA 5 in a range from 0 to 10 μg. Similarly, to determine silencing potency of pU6 shRNA 5 against pCH-9/3091, pU6 shRNA 5 was transfected in a range from 0 to 10 μg. A constant amount of 1 μg of pCMV miR-31/8 and pCH-9/3091 was transfected in each well. Backbone plasmid was included in each case to ensure that equal amounts of total plasmid DNA was transfected. A plasmid vector that constitutively produces eGFP [43] was also included in each cotransfection to verify equivalent transfection efficiencies using fluorescence microscopy. Transfection was carried out with 800 ng of shRNA- or miR-expressing plasmid using Lipofectamine (Invitrogen, CA, USA) according to the manufacturer's instructions. To generate psi-CHECK-8T, which contained the miR 8 target, primer 8T forward 5′-CAA TGT CAA CGA CCG ACC TT-3′ and primer 8T reverse 5′-ACT AGT GCC TCA AGG TCG GT-3′ were used to amplify nucleotides 1678 to 1702 of the HBV genome and introduce a Spe I site at the 3′ end of the amplicon. Purified fragment was ligated into the pTZ-57R/T PCR cloning vector and the insert was removed with Sal I and Spe I and ligated into the Xho I and Spe I sites of psi-CHECK 2.2 (Promega, WI, USA) to generate psi-CHECK-8T with the HBV target site downstream of the Renilla luciferase ORF. All plasmid sequences were verified according to standard dideoxy chain termination protocols (Inqaba Biotechnology, South Africa).
Assessment of miR shuttle effects on independent RNAi-mediated silencing. To determine the effect of miR-expressing vectors on independent RNAi-mediated gene silencing, a dual luciferase reporter plasmid (psi-CHECK-8T) containing an independent HBV miR-31/8 target sequence downstream of the Renilla luciferase ORF was transfected together with pCMV miR-31/8 and each of the shRNA 5-, miR-31/5- or miR-122/5-expressing vectors (
Hydrodynamic injection of mice and measurement of hepatic luciferase activity. To determine effects of miR on reporter gene activity in vivo, BALB/c mice received 0.5 μg reporter target DNA (psi-CHECK-8T), 5 μg pCH-9/3091, combinations of anti HBV plasmids (pCMV miR-31/8, pU6 shRNA 5, pCMV miR-31/5 or pCMV miR-122/5) or mock (pCI-neo backbone). Mice were sacrificed 3 days after HDI, their livers harvested, homogenized in phosphate buffered saline and activities of Renilla and Firefly luciferase were determined as described above.
Assessment of toxicity and disruption of independent RNAi-mediated silencing. To assess possible disruption of independent RNAi-mediated silencing, as well as toxicity in vivo caused to hepatocytes by pri-miR shuttles, mice were also injected with the psi-CHECK-8T dual luciferase reporter plasmid and various anti HBV expression cassettes (
The human Alpha-1-antitrypsin (A1AT) and Factor VIII (FVIII) promoters were amplified from total genomic DNA extracted from Huh7 cells using the primer sets in Table 1. The HBV Basic Core Promoter (BCP) and PreS2 promoter were amplified from the plasmid pCH-9/3091 using the primer sets in Table 1. All oligonucleotides were synthesised by standard phosphoramidite chemistry (Inqaba Biotechnology, South Africa). Primers were designed such that amplification introduced a BgIII (BclI in the case of A1AT) site at the 5′ end and a HindIII site at the 3′ end of the amplicons. Promoter sequences were amplified using the Expand High. Fidelity PCRPLUS System (Roche, Germany) according to manufacturer's instructions. PCRs were set up in 50 μl reaction mixtures and contained 5× Expand HiFiPLUS Buffer (with MgCl2), 0.2 mM dNTPs (dGTP, dATP, dTTP and dCTP), 0.5 μM of respective forward and reverse primers, 2.5 U Expand HiFiPLUS Enzyme Blend and 50 ng of genomic DNA of 100 pg plasmid DNA. The PCR conditions were as follows: Initial denaturation at 94° C. for 2 minutes; 30 cycles of denaturation at 94° C. for 30 seconds, annealing at 55° C. for 30 seconds and extension at 72° C. for 3 minutes (during cycles 20-30 extension time increased by 10 seconds every cycle); and a final extension at 72° C. for 7 minutes.
The PCR products were subjected to agarose gel electrophoresis and eluted using the MinElute™ Gel Extraction Kit (Qiagen, Germany). Purified fragments were ligated into the PCR cloning vector pTZ57R/T (InsTAclone PCR Cloning Kit, Fermentas, WI, USA). A 1:3 molar ratio of vector to insert was ligated at 16° C. overnight. Chemically competent E. coli (XL1-Blue, Invitrogen, CA, USA) were transformed with the ligation mixes and plated on Luria Bertani ampicillin-, X-gal-, and IPTG-containing agar plates then incubated at 37° C. overnight. Colonies positive for an insert (white colonies) were selected for plasmid purification. Plasmids were subjected to restriction enzyme digestion and clones yielding desired results were sequenced (Inqaba Biotechnology, South Africa). Next, the CMV immediate early enhancer promoter sequence within pCI-neo was substituted with the sequences of the liver-specific promoters (
To assess the functionality of the liver-specific expression vectors the sequence encoding Firefly luciferase was cloned downstream of the promoter sequences. The Firefly luciferase sequence was digested out of pCI-neo FLuc with NheI and SmaI and ligated into the equivalent sites of the liver-specific expression vectors to generate pCI-A1AT FLuc, pCI-FVIII FLuc, pCI-BCP FLuc and pCI-PreS2 FLuc.
The human hepatoma cell line, Huh7 and the Human Embryonic Kidney derivatives, 116 cells were maintained in DMEM growth medium (Sigma, Mo., USA) supplemented with 10% foetal calf serum (Gibco BRL, UK). One day prior to transfection cells were seeded at a density of 40% into 24-well dishes (Corning Inc., NY, USA).
Cells were transfected with 100 ng of the different Firefly luciferase expression vectors, 100 ng of phRL-CMV and 100 ng of pCI-neo eGFP. The plasmid DNA was mixed with 50 μl of Opti-MEM (Invitrogen, CA, USA) and incubated at room temperature for 5 minutes. An additional 50 μl of Opti-MEM was mixed with 0.5 μl of Lipofectamine 2000 (Invitrogen, CA, USA) and also incubated for 5 minutes at room temperature. After the incubation period the DNA:Opti-MEM and Lipofectamine:Opti-MEM mixtures were combined and incubated for an additional 20 minutes at room temperature to allow lipid:DNA complexes to form. Following the second incubation period 100 μl of the transfection mix was added per well to the 24-well dish. Transfections were repeated in triplicate. The cells were incubated for 5 hours at 37° C. and 5% CO2. Thereafter the growth medium was replaced with fresh medium and the cell incubated for 48 hours.
Fourty eight hours post-transfection cells were assay for in situ luciferase activity using the Dual Luciferase Assay System (Promega, WI, USA). Briefly, growth medium was removed and the cells lysed with 100 μl of Passive Lysis Buffer with agitation for 15 minutes. Ten microlitres of the cell lysates were dispensed into a luminometer plate and Firefly luciferase and Renilla luciferase activities measured using the Veritas Dual Injection Luminometer (Turner BioSystems, CA, USA).
Generation of Liver-Specific miRNA Shuttle Vectors
To generate liver-specific miRNA shuttles vectors the pri-miR-122 shuttles were digested from pCI-miR-12215, pCI-miR-122/6 and pCI-miR-122/10 with NheI and SmaI and ligated into the equivalent sites of pCI-A1AT, pCI-FVIII, pCI-BCP and pCI-PreS2.
Assessing Functionality of Liver-Specific miRNA Shuttle Vectors
Twenty-four hours before transfection, cells were seeded into 24-well dishes at a density of 40%. Cells were transfected with 80 ng of target plasmid (pCH-FLuc), 800 ng of the different miRNA shuttle vectors, 50 ng of phRL-CMV and 50 ng of pCI-neo eGFP. Plasmid DNA was made up to a total of 1 μg with pCI-neo and diluted with 50 μl of Opti-MEM. One microlitre of Lipofectamine 2000 was diluted in 50 μl of Opti-MEM. Transfections and measurement of Firefly and Renilla luciferase activities were carried out as described above.
Transfection of cultured mammalian cells with vectors expressing Firefly luciferase allowed for the convenient measurement of luciferase as an indicator of (i) functionality of constructed vectors and (ii) ability of vectors to exhibit tissue-specificity. The promiscuous and constitutively active CMV promoter expressing Firefly luciferase was included as a positive control for expression.
Expression Vectors are Capable of Tissue-Specific Expression of miRNA Shuttles
Having demonstrated tissue-specific expression of the vectors the next step was to test whether or not these vectors could silence HBV replication in a tissue-specific manner. The anti HBV pri-miR-122-derived shuttles were cloned downstream of the liver-specific promoters and their ability to inhibit markers of HBV replication selectively in liver-derived cells only was tested.
Rationale. By generating cassettes that are capable of targeting multiple HBV sites simultaneously, the efficacy of silencing of viral replication should be improved. Moreover, a combination of RNAi effecters that act at different cognate sites of the virus will limit the chances of viral escape and resistance to the inhibitory effects of anti HBV pri-miR shuttles. The schematic illustration of the cassettes that generate the trimeric pri-miR cassettes used here against HBV is shown in
miR-derived anti HBV sequences. DNA encoding pre-miR-31 mimics containing the guide sequence targeting HBV coordinates 1775 to 1797 (target 5) (SEQ ID NO: 3 (135)), 1678 to 1700 (target 8) (SEQ ID NO: 7 (137)) and 1574 to 1596 (target 9) (SEQ ID NO: 8 (138)) were generated by primer extension of paired forward and reverse oligonucleotides. Oligodeoxynucleotides encoding the pre-miR sequences were synthesised using phosphoramadite chemistry (Inqaba Biotech, South Africa). Primer extensions were performed as PCR using Promega's PCR Master Mix (Promega, WI, USA). The thermal cycling conditions were as follows: Initial denaturation at 94° C. for 5 minutes, followed by 30 cycles of denaturation at 94° C. for 10 seconds, annealing at 50° C. for 10 seconds and extension at 72° C. for 10 seconds and a final extension step at 72° C. for 10 minutes. The sequences of the oligonucleotides encoding the anti HBV miR shuttles were:
The primer extended products were subjected to standard agarose gel electrophoresis (1% gel), excised and extracted from the gel slice using Qiagen's MinElute™ Gel Extraction Kit (Qiagen, Germany). Approximately 100 ng of purified amplicons were used as template and amplified with universal forward and reverse pri-miR-31 primers that had the following sequences.
The purified DNA fragments were ligated into pTZ-57R/T (InsTAclone™ PCR Cloning Kit, Fermentas, Hanover, Md., USA) to generate pTZ-57R/T pri-miR-31/5 and pTZ-57R/T pri-miR-122/5 respectively. Ligation and selection were carried out according to the manufacturer's instructions. Briefly, the ligation reactions were incubated at 22° C. for 2-3 hours. Chemically competent E. coli were transformed with the ligation mix, plated on ampicillin, IPTG, X-gal positive LB agar plates and the plates incubated at 37° C. overnight. Clones positive for insert and in the reverse orientation (relative to the β-galactosidase gene) were sequenced according to standard dideoxy chain termination protocols (Inqaba Biotechnology, South Africa).
Multimeric pri-miR shuttle cassettes expressed from an RNA polymerase II promoter were generated by inserting combinations of pri-miR-31/5, -31/8 and 31/9 sequences downstream of the CMV immediate early promoter enhancer (
HEK283 cells were harvested 2 days after transfection of a 40% confluent 10 cm diameter culture dish with 10 μg of RNAi effecter plasmid and total RNA was extracted using Tri Reagent (Sigma, Mich., USA) according to the manufacturer's instructions. Thirty μg of RNA was resolved on urea denaturing 12.5% polyacrylamide gels and blotted onto nylon membranes. Blots were hybridised to three DNA oligonucleotides which were complementary to anti HBV guides 5, 8 and 9. Probes were labelled at their 5′ ends with [α-32P]ATP and T4 polynucleotide kinase. After purification using standard procedures, they were hybridized to immobilised RNA, exposed to X-ray film then stripped and reprobed. An oligonucleotide sequence complementary to U6 snRNA was used as a control for equal loading of the cellular RNA. Probe oligonucleotide sequences were:
To generate dual luciferase targets containing the anti HBV miR 5, anti HBV miR 8 and anti HBV miR 9 targets, primers were used to amplify HBV DNA and introduce a Spe I site at the 3′ end of the amplicon. Primer sequences to amplify the targets were as follows:
Purified fragment was initially ligated into the pTZ-57R/T PCR cloning vector and the insert was removed with Sal I and Spe I and ligated into the Xho I and Spe I sites of psi-CHECK 2.2 (Promega, WI, USA) to generate psi-CHECK-5T, psi-CHECK-8T and psi-CHECK-9T with the HBV target site downstream of the Renilla luciferase ORF. All plasmid sequences were verified according to standard dideoxy chain termination protocols (Inqaba Biotechnology, South Africa).
The pCH-9/3091 plasmid has been described previously and above [42]. Culture and transfection of Huh7 and HEK293 lines was carried out as has been described [39]. Measurement of HBsAg was carried out using the Monolisa (ELISA) immunoassay kit (BioRad, CA, USA) as described above. Ratios of 10:1 and 1:1 of U6 shRNA 5 vector to pCH9/3091 were tested, but for all other combinations, the ratio of RNAi expressing vector to pCH9/3091 was 10:1. Using a 12 well culture dish format, cells received 100 ng of pCH9/3091 and 1 μg of RNAi effecter plasmid. A plasmid vector that constitutively produces eGFP [43] was also included in each cotransfection and equivalent transfection efficiencies were verified by fluorescence microscopy.
Assessment of multimeric miR shuttle-mediated silencing. To determine the effect of miR-expressing vectors on reporter gene silencing, dual luciferase reporter plasmids (psi-CHECK-5T, psi-CHECK-8T and psi-CHECK-9T) containing independent target sequences were transfected together with pri-miR shuttle-expressing vectors. A plasmid vector that constitutively produces eGFP [43] was also included in each cotransfection to verify equivalent transfection efficiencies using fluorescence microscopy. The activities of Renilla and Firefly luciferase were measured with the dual luciferase assay kit (Promega, WI, USA) and using the Veritas dual injection luminometer (Turner BioSystems, CA, USA).
Statistical Analysis. Analysis of statistically significant differences was carried out using the student's paired two-tailed t-test. Calculations were made with the GraphPad Prism software package (GraphPad Software Inc., CA, USA).
Northern Blot Analysis of RNA from Cells Transfected with Trimeric miR Expression Cassettes
Northern blot hybridisation of RNA extracted from cells that had been transfected with multimeric expression cassettes followed by probing for guide sequences complementary to each of the guides of HBV targets 5, 8 and 9 are shown in
To assess the efficacy of knockdown, the dual luciferase assay was undertaken on lysates from cells that had been cotransfected with plasmids expressing pri-miR-expressing cassettes together with the psiCHECK-derived vectors that had individual HBV targets inserted downstream of the Renilla luciferase open reading frame (
The effect of the multimeric pri-miR expression cassettes on the secretion of HBsAg from transfected liver cells in culture was also determined (
Collectively, these data demonstrate that trimeric pri-miR expression cassettes are capable of generating individual anti HBV guide sequences that are efficient silencers of reporter gene constructs that include HBV targets. The efficiency of guide sequence generation is not uniform, and may be dependent on inherent sequence characteristics of the miR shuttles (e.g. lower processing and silencing achieved by pri-miR 9 shuttles) as well as the surrounding pri-miRs (e.g. diminished pri-miR 8 silencing achieved when located immediately downstream of the pri miR 9 sequence).
The DNA sequence for the HCV 5′ UTR region cloned into pTAG-A was a gift from Prof Richard M. Elliot, Institute of Virology, University of Glasgow, U.K. pGL3-Basic, Dual-Glo™ Luciferase Assay System, and pGEM®-T Easy Vector Kit was from Promega, USA. BenchTop 1 kb DNA ladder, InsTAclone™ PCR Cloning Kit and PCR Master Mix (2×) was from Fermentas, Lithuania. Oligonucleotide primers were from IDT, USA. Restriction enzymes PstI, EcoRI, XhoI and XbaI were from New England Biolabs, USA. α-D-Galactopyranoside (X-gal), Ampicilin, Lipofectamine 2000™ were from Sigma, UK. QIAprep Spin Miniprep Kit and QIAGEN Endofree Maxi-prep kit were from Qiagen, Germany. RPMI, FCS, Penicillin/Streptomycin, and OptiMEM were from Gibco, UK. Nucleospin Kit was from Machery-Nagel, Germany. The Veritas™ Microplate Luminometer was from Turner Biosystems, USA.
The DNA sequence for the HCV 5′ UTR region (SEQ ID NO: 34) was amplified using PCR with plasmid construct pTAG-A as template, forward primer F5′UTRXhoI (ATT ACT CGA GTT CAC GCA GAA AGC GTC; SEQ ID NO: 96) and reverse primer R5′UTREcoRI (ATT AGA ATT CGA ACT TGA CGT CCT GTG G; SEQ ID NO: 97). F5′UTRXhoI and R5′UTREcoRI consisted of four spacer 5′-terminal nucleotides, ATTA, the 6-nt recognition sequences for XhoI and EcoRI restriction endonucleases respectively for future directional cloning and screening purposes, and complementary sequences to the 5′ and 3′ ends of the HCV 5′ UTR region respectively which included between them the first 351 nt of the HCV transcript.
The coding region for firefly luciferase was similarly amplified using pGL-3-Basic as a template, forward primer FLucEcoRI (ATT AGA ATT CAT GGA AGA CGC CAA AAA C; SEQ ID NO: 98) and reverse primer RLucXbaI (ATT ATC TAG ATT ACA CGG CGA TCT TTC C; SEQ ID NO: 99). FLucEcoRI and RLucXbaI consisted of four spacer 5′-terminal nucleotides, ATTA, the 6-nt recognition sequences for EcoRI and XbaI restriction endonucleases respectively for future directional cloning and screening purposes, and complementary sequences to the 5′ and 3′ ends of the firefly luciferase coding sequence respectively which included between them the full length of 1653 nt.
The PCR reactions contained template DNA [2 μl, 100 ng]; forward primer [1 μl of 100 μM]; reverse primer [1 μl of 100 μM]; PCR Master Mix (2×) [25 μl] in a final volume of 50 μl. The PCR reaction conditions were 94° C., 2 min; 94° C. for 30 s, 55° C. for 1 min, 72° C. for 2.5 min, 30 cycles; 72° C., 10 min.
The length of the PCR products was confirmed by agarose gel electrophoresis as described in Example 1. BenchTop 1 kb DNA ladder was resolved as a molecular marker. The resolved PCR products were visualized under UV radiation.
PCR product [1 μl] from the HCV 5′UTR and firefly luciferase PCR reactions were ligated into pGEM-T [1 μl] to produce pGEM-T-UTR and pGEM-T-LUC respectively, using the pGEM®-T Easy Vector Kit, in a ligation reaction containing 2× rapid ligation buffer [5 μl]] and T4 ligase enzyme [3U, 1 μl] in a final volume of 10 μl. The ligation reaction was incubated at 15° C. overnight before being transformed [5 μl] into competent Escherichia coli DH5α [50 μl]. The transformation reaction [55 μl] was incubated on ice for 30 mins, heat pulsed at 42° C. for 2 mins, and incubated on ice for 2 mins before being plated out onto 2×YT broth agar plates containing 0.1 mg/ml ampicillin, spread with α-D-Galactopyranoside (X-gal) [40 μl, 20 mg/ml in DMSO]. Competent E. coli DH5α cells were prepared according to standard protocols. The plates were incubated at 37° C. for 16 hours.
Putative plasmid DNA was extracted from the E. coli cultures of transformants exhibiting white colonies for the pGEM-T-UTR and pGEM-T-LUC transformations by a modified standard alkaline lysis method using the QIAprep Spin Miniprep Kit as described in Example 1. The putative plasmid DNA was then screened by restriction with 5 U EcoRI as described in Example 1 in the buffer supplied by the manufacturer. Plasmid DNA exhibiting DNA fragments of the expected length were used for further cloning steps.
Cloning of the HCV 5′ UTR Target Expression Construct (pCineoUTRLUC)
Bulk restriction endonuclease digestions were prepared of pGEM-T-UTR, pGEM-T-LUC, and pCineoHBX plasmid DNA. pGEM-T-UTR was restricted with XhoI and EcoRI, pGEM-T-LUC with EcoRI and XbaI, and pCineoHBX with XhoI and XbaI. pCineoHBX was used instead of pCineo in order to better isolate the double-restricted pCineo vector fragment. Bulk digestions consisted of plasmid DNA [60 A 200 ng/μl], 10× EcoRI buffer, first enzyme [20 U, 4 μl], second enzyme [20 U, 4 μl], and water [22 μl]. The bulk digestions were incubated at 37° C. for 1.5 hours, resolved by agarose gel electrophoresis as before and gel purified. For gel purification: the appropriate bands were excised out of the gel and extracted using the Nucleospin Kit. Briefly, buffer BT [300 μl] was added to the excised piece of gel and the agarose sample incubated at 50° C. for 10 mins with frequent inversion. The melted agarose sample was loaded onto a nucleospin column and centrifuged at 12 000×g for 30 s. The nucleospin column was then washed twice with buffer NT3 [700 μl] by centrifugation. The bound DNA was eluted by the addition of elution buffer NE [50 μl, 5 mM Tris-HCl, pH 8.5,] followed by centrifugation at 12 000×g for 1 min.
Eluted DNA fragments were ligated together in a ratio of 1:3:3 of 5′UTR:LUC:pCineo [1 μl:3 μl:3 μl] in a ligation reaction containing 2× rapid ligation buffer [10 μl] and T4 ligase enzyme [3U, 1 μl] in a final volume of 21 μl. The ligation reaction was incubated at 15° C. overnight and transformed into competent E. coli DH5α as before. The putative plasmid DNA was extracted and screened by restriction as before with 5 U SphI in 1× Buffer Tango [3.3 mM Tris-acetate, pH 7.9 at 37° C., 1 mM magnesium acetate, 6.6 mM potassium acetate, 0.1 mg/ml BSA]. Bulk DNA was prepared as described in Example 1.
In Silico Design of sh260 and miR260
The structure of miR-30 (
Cloning of the sh260 and miR260 Expression Constructs (pTz57R-sh260 and pTz57R-miR260)
The DNA sequence for the U6 promoter was PCR amplified in a two-step PCR reaction during which the DNA sequence of either sh260 or miR260 was inserted downstream from the U6 promoter.
For sh260: The forward primer, FU6 (ATT AGA ATT CAA GGT CGG GCA GGA AGA G) (SEQ ID NO: 100), complementary to 24-nt of the 5′-end of the U6 promoter and four spacer 5′-terminal nucleotides, ATTA, was used for all PCR steps. In the first round of PCR, the reverse primer, RU6-sh260-1 (ACC CCC ATC TGT GGC TTC ACA GGG TGC ACG GGA TCT ACG AGA CCT TCG CCG GTG TTT CGT CCT TTC C) (SEQ ID NO: 101) was used. In the second round of PCR, the reverse primer, RU6-sh260-2 (GTC GAC AAA AAA GCA GAG GTC TCG TAG ACC GTG CAC CCC CAT CTG TGG CTT CAC AGG) (SEQ ID NO: 102) was used.
For miR260: The forward primer, FU6 (ATT AGA ATT CM GGT CGG GCA GGA AGA G) (SEQ ID NO: 103), complementary to 24-nt of the 5′-end of the U6 promoter and four spacer 5′-terminal nucleotides, ATTA, was used for all PCR steps. In the first round of PCR, the reverse primer, RU6-miR31-260-1 (GCT TCC CAG TTC AAG AGG TCT CGT AGA CCG TGC ACT CCT CTC CAG TTC CGA GTT ACA GCG GTG TTT CGT CCT TTC C) (SEQ ID NO: 104) was used. In the second round of PCR, the reverse primer, RU6-miR31-260-2 (GTC GAC MA AM GCT GCT GTC CAG ACA GGA AAG ATG TGC ATG GTA TAC GAG ACC AGC TTC CCA GTT CM GAG GTC TC) (SEQ ID NO: 105) was used.
The first PCR reaction contained pTz57-U6 template [1 μl, 100 ng]; FU6 primer [1 μl of 6 mM]; reverse primer [2 μl of 6 mM]; dNTPs [1 μl of 100 mM]; GoTaq® PCR System enzyme [0.5 μl]; and GoTaq® PCR System 10× Buffer [5 μl] in a final volume of 50 μl. The PCR reaction conditions were 94° C., 2 min; 94° C. for 30 s, 55° C. for 1 min, 72° C. for 2.5 min, 30 cycles; 72° C., 10 min. The second PCR reaction contained the same reagents as the first except for the replacement of the template and the reverse primer. One microliter of this first PCR reaction mixture was used as template and re-amplified in the second round of PCR using the same forward primer FU6 and the second reverse primer.
The length of the PCR products from the second round of PCR was confirmed by agarose gel electrophoresis and ligated into pTz57R/T. Briefly, PCR products [5 μl] of the first and second PCR reactions were each added to agarose gel loading buffer [5 A 30% glycerol v/v, 0.25% w/v bromophenol blue] and resolved on an agarose gel [50 ml, 0.8% w/v] containing ethidium bromide [0.5 μg/ml], in TBE buffer [45 mM Tris, 45 mM Borate, 1 mM EDTA, pH 8.3] at 100 V for 2 hours. PstI-digested lamda DNA was resolved as a molecular marker. The resolved PCR products were visualized under UV radiation. Putative pTz57R-sh260 transformants and putative pTz57R-miR260 transformants were screened by EcoRI restriction enzyme digestion as described in Example 1, and the digested fragments resolved by agarose gel electrophoresis as previously described. Putative pTz57R-sh260 was also confirmed by PCR by PCR amplification of extracted plasmid DNA using FU6 and RU6-sh260-2 under amplification conditions as described above. Purified pTz57R-sh260 and pTz57R-miR260 were prepared using the QIAGEN Endofree Maxi-prep Kit according to manufacturer's instructions.
The human hepatoma cell line, Huh-7, was maintained in RPMI media supplemented with 10% fetal calf serum (FCS), penicillin (100 U mL−1) and streptomycin (100 U mL−1) [complete media] in a humidified atmosphere, at 37° C. with 5% CO2. Cells were typically subcultured every 2 to 3 days and maintained in 6 cm dishes. All solutions were preheated before use. Cells were trypsinized in 1×Trypsin/EDTA at 37° C. for 3-5 mins. The trypsin reaction was stopped by the addition of an equal volume DMEM containing 10% FCS, and the cells collected by centrifugation at 2000 rpm for 2 mins in a desk-top centrifuge. The cell pellet was resuspended in complete media [5 ml] and the suspension used to seed [1 ml] fresh complete media [15 ml] in a 6 cm dish.
Co-Transfection of HuH-7 Cells with pCineoUTRLUC, pCMV-Ren, pTz57R-sh260, and pTz57R-miR260 and HCV 5′UTR Knockdown Analysis by Luminescence Measurement
HuH-7 cells were transiently co-transfected in triplicate with pCineoUTRLUC, pCMV-Ren, and pTz57R-sh260, or pCineoUTRLUC, pCMV-Ren, and pTz57R-miR260, or pCineoUTRLUC, pCMV-Ren, and pTz57R-miR118 (an expression construct expressing a miR31 hairpin targeting Hepatitis C Virus with poor efficiency and used here as a negative control) using Lipofectamine 2000™ in 6 well plates seeded to 60% confluency, according to manufacturer's instructions. pCMV-Ren was used to express Renilla luciferase as an internal efficiency of transfection control. Each transfection contained pCineoUTRLUC [100 ng], pCMV-Ren [50 ng], and pTz57R construct [1 μg]. Plasmid DNA: Lipofectamine 2000™ complex solutions were prepared per reaction as follows: pre-warmed Lipofectamine 2000™ [4 μl per reaction] was added to OptiMEM [150 μl per reaction] and allowed to incubate at room temperature for 15 mins. Plasmid DNA [1.06 μg total DNA per reaction] was added to OptiMEM [150 μl per reaction] and allowed to incubate at room temperature for 15 mins. The Lipofectamine 2000™ and plasmid DNA solutions were then combined, mixed gently by pipetting and allowed to complex at room temperature for 15 mins to produce a transfection reaction.
12 well dishes seeded to 60% confluency were washed with PBS. Each separate transfection reaction was then added to a well and incubated in a humidified atmosphere, at 37° C. with 5% CO2 for 2 hours. The transfection reaction was then removed, complete media [2 ml] added, and the dishes incubated for 48 hours in a humidified atmosphere, at 37° C. with 5% CO2.
To assess HCV 5′ UTR knockdown, luciferase expression was assessed using the Dual-GIo™ Luciferase Assay System. After the 48 hour incubation, the transfected cells were washed three times with PBS before the addition of 1×PLB buffer 0004 directly to the cells followed by gentle rocking at room temperature for 30 mins. Cell lysate [20 μl] was then dispensed from each transfection well into a well of a whiote opaque luminometer microtitre plate. Luminescence measurements were taken using the Veritas™ Microplate Luminometer. The P and M injectors were primed with Luciferase Assay Reagent II (LARII) and Stop and Glo reagent respectively. The microtitre plate was placed in the luminometer and LARII [100 μl] injected into each well before the luminescence was read with a 2 s premeasurement delay and a 10 s integration to detect firefly luciferase. Stop and Glo [100 μl] was the injected per well with the M injector and the luminescence read with a 2 s premeasurement delay and a 10 s integration to detect renilla luciferase. The experiment was repeated. The readings were analysed by calculating a firefly/renilla luminescence ratio and normalizing the ratio value obtained for the pTz57R-sh260 and the pTz57R-miR260 transfections against that obtained for the pTz57R-miR118 transfection. Statistical differences were calculated using the Students T-Test.
The HCV 5′UTR and firefly luciferase PCR amplification successfully yielded a 346 by and a 1653 by DNA product (
Design of sh260 and miR31-260 and Cloning pTz57R-sh260 and pTz57R-miR31260
The predicted structure of the miR-30 [41] (
Cloning of the sh260 and miR260 Expression Constructs (pTz57R-sh260 and pTz57R-miR260)
pTz57R-sh260: The length of the PCR products from the two-step PCR reaction was confirmed by agarose gel electrophoresis to be approximately 347 by for the products of the first PCR reaction (
pTz57R-miR260: The length of the PCR products from the two-step PCR reaction was confirmed by agarose gel electrophoresis to be approximately 323 by for the products of the first PCR reaction (
Expression of miR260 Results in Better HCV5′UTR Knockdown than sh260
To determine whether sh260 and miR260 knocked down expression of the HCV 5′UTR region, we fused the 5′ UTR to the firefly luciferase indicator gene. Both sh260 (p=0.000562004) and miR260 (p=9.96473E-05) were able to significantly knock down the expression of the indicator gene when compared to the negative control of miR118 (
While the invention has been described in detail with respect to specific embodiments thereof, it will be appreciated by those skilled in the art that various alterations, modifications and other changes may be made to the invention without departing from the spirit and scope of the present invention. It is therefore intended that the claims cover or encompass all such modifications, alterations and/or changes.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2007/04435 | May 2007 | ZA | national |
This application is continuation under 35 U.S.C. §§120 and 365(c) of International Application PCT/IB2008/052103, filed on May 29, 2008. This application also claims priority under 35 U.S.C. §119 of South Africa Application No. 2007/04435, filed on May 29, 2007. The disclosures of PCT/|B2008/052103 and ZA 2007/04435 are incorporated herein by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/IB2008/052103 | May 2008 | US |
| Child | 12627940 | US |
